These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16086639)

  • 1. Haemophilia B: Christmas disease.
    Giangrande P
    Expert Opin Pharmacother; 2005 Aug; 6(9):1517-24. PubMed ID: 16086639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 4. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 8. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
    Limentani SA
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.
    Barnbrock A; Heller C; Königs C; Budde U; Schwabe D
    Haemophilia; 2016 Sep; 22(5):e437-9. PubMed ID: 27353656
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
    Young G; McDaniel M; Nugent DJ
    Haemophilia; 2005 May; 11(3):203-7. PubMed ID: 15876264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of third molar removal with a single dose of recombinant Factor IX (BeneFIX) and local measures in severe haemophilia B.
    Hewson ID; Makhmaloaf P
    Aust Dent J; 2010 Sep; 55(3):322-4. PubMed ID: 20887522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the management of haemophilia and christmas disease.
    Biggs R
    Clin Haematol; 1979 Feb; 8(1):95-114. PubMed ID: 367667
    [No Abstract]   [Full Text] [Related]  

  • 13. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EHL-FIX in haemophilia B carriers with FIX deficiency.
    Marlière C; Maindiaux L; Lambert C; Hermans C
    Haemophilia; 2020 Mar; 26(2):e38-e40. PubMed ID: 31840356
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of the new generation recombinant factor concentrates.
    Schlesinger KW; Ragni MV
    Expert Opin Drug Saf; 2002 Sep; 1(3):213-23. PubMed ID: 12904137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Haemophilia].
    Loomans JI; Lock J; Peters M; Leebeek FW; Cnossen MH; Fijnvandraat K
    Ned Tijdschr Geneeskd; 2014; 158():A7357. PubMed ID: 25351381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.